Risk for end-stage renal disease over 25 years in the population-based wesdr cohort

Diabetes Care

Volumn 37, Issue 2, 2014, Pages 381-388

  LeCaire, Tamara J ^a   Klein, Barbara E K ^a   Howard, Kerri P ^a   Lee, Kristine E ^a   Klein, Ronald ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROLIFERATIVE RETINOPATHY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; EPIDEMIOLOGY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PRESCHOOL CHILD; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; WISCONSIN; YOUNG ADULT;

EID: 84893083410     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1287     Document Type: Article

References (38)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164- 176
2. U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
3. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074- 1079
4. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia 2012;55:2301-2306
5. Finne P, Reunanen A, Stenman S, Groop P-H, Gr?onhagen-Riska C. Incidence of end- stage renal disease in patients with type 1 diabetes. JAMA 2005;294:1782- 1787
6. M?ollsten A, Svensson M, Waernbaum I, et al.; Swedish Childhood Diabetes Study Group; Diabetes Incidence Study in Sweden; Swedish Renal Registry.Cumulative risk, age at onset, and sexspecific differences for developing endstage renal disease in young patients with type 1 diabetes: a nationwide populationbased cohort study. Diabetes 2010;59: 1803-1808
7. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year naturalhistory of type 1 diabetes complications: the Pittsburgh Epidemiology of iabetes Complications Study experience. Diabetes 2006;55:1463-1469
8. Nishimura R, Dorman JS, Bosnyak Z, Tajima N, Becker DJ, Orchard TJ; Diabetes Epidemiology Research International Mortality Study; Allegheny County Registry. Incidence of ESRD and survival after renal replacement therapy in patientswith type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003;42: 117-124
9. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011;22:545-553
10. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: 22 the twenty-five-year progression of retinopathy in persons with type 1diabetes. Ophthalmology 2008;115:1859- 1868
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. 2. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102: 520-526
12. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. 9. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107: 237- 243
13. Klein R, Klein BEK, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999;22:743-751
14. Klein R, Klein BE,Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: 17. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815
15. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Studyof Diabetic Retinopathy. Arch Intern Med 2004;164:1917-1924
16. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. Wisconsin Epidemiology Study of Diabetes Retinopathy. 12. Relationship of C-peptide and diabetic retinopathy. Diabetes 1990;39:1445-1450
17. Writing Committee on Behalf of the HDFP Cooperative Group. The hypertension detection and follow-up program: hypertension detection and follow-up program cooperative group. Prev Med 1976;5:207-215
18. Klein R, Moss S; Diabetes Control and Complications Trial Research Group. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995;155:745-754
19. Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and 16-year incidence of chronic kidney disease in type 1 diabetes.Exp Clin Endocrinol Diabetes 2007;115:203-206
20. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612 21
21. SAS Institute Inc. SAS/STAT 9.3 User'sGuide. Cary, North Carolina, SAS Institute Inc., 2011
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706
23. SAS Institute Inc. Parameterizing models to test the hypotheses you want: coding indicator variables and modified continuous variables. In Proceedings of the 30th Annual SAS Users Group International Conference, Philadelphia, Pennsylvania, 2005. Cary, North Carolina, SAS InstituteInc., paper 212-30
24. Baron RM, Kenny DA. The moderatormediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on thedevelopment and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
26. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532- 2539
27. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33:73-77
28. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-794
29. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996;50:2041-2046
30. MatsushimaM, Tajima N, LaPorte RE, et al.; Diabetes Epidemiology Research International (DERI) U.S.-Japan Mortality Study Group. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patientsin Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetologia 1995;38:236-243
31. LeCaire TJ, Palta M, Klein R, Klein BEK, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2013;36:631-637
32. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-1264
33. Forsblom C, Harjutsalo V, Thorn LM, et al.; FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011; 22:537-544
34. Costacou T, Fried L, Ellis D, Orchard TJ. Sex differences in the development of kidney disease in individuals with type 1 diabetes mellitus: a contemporary analysis. Am J Kidney Dis 2011;58:565-573
35. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving H-H. Improved prognosis in type 1 diabeticpatients with nephropathy: a prospective follow-up study. Kidney Int 2005;68: 1250-1257
36. Hirst JA, Taylor KS, Stevens RJ, et al. The impact of renin-angiotensin-aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012;81:674-683
37. Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol 2012;32: 407-414
38. Klein R. Diabetic retinopathy and nephropathy. In The Diabetic Kidney. Totowa, NJ, Humana Press Inc., 2006,p. 473-498